ResultsIQ

ResultsIQ › Latest results › Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited strategy deck summary

NSE: GUJTHEM · BSE: 506879

Strategy deck of 22 May 2026, summarised by AI from the filing.

GTBL to acquire 100% of MicroBiopharm Japan for JPY 21.5 Bn (~₹1,300 cr), expected to close in Q2 FY2027.

Key takeaways

  1. Acquisition GTBL will acquire 100% equity in MicroBiopharm Japan Co., Ltd. via a wholly owned SPV incorporated in Japan.
  2. Consideration Consideration is JPY 21.5 Bn (~₹1,300 cr), funded through an optimal mix of debt and equity; transaction expected to be EPS accretive.
  3. Timeline Expected close is Q2 FY2027, subject to customary regulatory approvals and closing formalities.
  4. Risk Transaction is subject to customary regulatory approvals and closing formalities; no assurance it will be completed on the terms described or at all.

Original filing on BSE

Gujarat Themis Biosyn Limited Q1 FY27 results

As filed: Revenue ₹43.8 cr (+22% year on year), EBITDA ₹20.8 cr (+49% year on year), PAT ₹11.1 cr (+23% year on year), EBITDA margin 47.5% (+861 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹44.2 cr (+16% year on year), EBITDA ₹19.4 cr (+21% year on year), PAT ₹10.9 cr (−9% year on year), EBITDA margin 43.8% (+169 bps). Score 55 of 100, In line with trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: +8.8% in 30 days (Nifty 500: +2.1%).
  • Q3 FY26: Revenue ₹43.4 cr, EBITDA ₹21.3 cr, PAT ₹12.5 cr, EBITDA margin 49.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.3% in 29 days (Nifty 500: −4.0%).
  • Q2 FY26: Revenue ₹42.0 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 50.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.8% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹36.0 cr, EBITDA ₹14.0 cr, PAT ₹9.0 cr, EBITDA margin 38.9%. Not scored. No result for the same quarter last year. Share price after the results: −3.2% in 28 days (Nifty 500: −2.0%).
  • Q4 FY25: Revenue ₹38.0 cr, EBITDA ₹16.0 cr, PAT ₹12.0 cr, EBITDA margin 42.1%. Not scored. No result for the same quarter last year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Themis Biosyn Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.